Inluriyo (imlunestrant)
ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy ยท Oncology (ER+/HER2- metastatic breast cancer)
About Inluriyo
Inluriyo (imlunestrant) is an Oral selective estrogen receptor degrader / SERD (400 mg once daily) manufactured by Eli Lilly and Company, used in the treatment of ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. It received FDA approval in under the pathway.
Note: Fatima list; ex-US detail
Accessing Inluriyo through Reserve Meds
We help patients in the Middle East, India, Africa, and other regions access Inluriyo via established Named Patient Program (NPP) and personal-import pathways. Every order requires a prescription from a licensed physician in the destination country.
What we need from you
- A prescription from a licensed physician in your country of residence.
- A clinical justification from the prescribing physician (why Inluriyo for this patient).
- Destination-country NPP or personal-import paperwork (we help prepare these).
- Patient consent for cross-border drug import under the applicable pathway.
Typical timeline
From request to delivery, most orders for Inluriyo are completed in 2-6 weeks. Timing varies by destination country regulatory review speed and physician documentation turnaround.
Indication context
ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. The condition falls within Immunology. For patients with this condition in countries where Inluriyo is not yet registered, NPP access is typically the primary legal pathway for obtaining treatment.
About the manufacturer
Inluriyo is manufactured by Eli Lilly and Company. We source drug supply exclusively through DSCSA-compliant US specialty wholesalers, ensuring every unit is authentic, serialized, and chain-of-custody documented.
International regulatory status
- United States: FDA approved ().
- EMA (EU): Status unknown.
- MHRA (UK): Status unknown.
- Other countries: Approval status varies. Reserve Meds coordinates access under each destination country's NPP pathway.
Start a request for Inluriyo
If you or a family member needs Inluriyo and it is not available in your country, submit a request. Our clinical team will review eligibility and reach out as our first cohort opens.
Inluriyo, country access pages
Information on how patients in different countries access Inluriyo through Named Patient Program pathways.
- Inluriyo in United Arab Emirates, The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
- Inluriyo in Saudi Arabia, The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
- Inluriyo in India, India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
- Inluriyo in Kuwait, Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
- Inluriyo in Qatar, Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
- Inluriyo in Bahrain, Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).
Access by country
Reserve Meds publishes a detailed country deep-dive for Inluriyo in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.